CASP7

Across TCGA pan-cancer cohorts, CASP7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CASP7 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CASP7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CASP7 expression acts as an unfavorable survival marker.

BRCA, HNSC, and CESC are the cancer types where CASP7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.565	0.924	<.001	36	view →
HNSC	OS	Median	II,III,IV	0.198	0.756	.002	21	view →
CESC	OS	Median	All	0.119	0.591	.002	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	III,IV	0.232	0.697	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CASP7–BRCA (OS)

Open the BRCA breakdown →